$1.08
0.00% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US1850631045
Symbol
CLSD
Sector
Industry

Clearside Biomedical, Inc. Stock price

$1.08
-0.02 1.82% 1M
-0.27 20.00% 6M
-0.09 7.69% YTD
+0.07 6.93% 1Y
-2.96 73.27% 3Y
-0.18 14.29% 5Y
-6.17 85.10% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.00 0.00%
ISIN
US1850631045
Symbol
CLSD
Sector
Industry

Key metrics

Market capitalization $81.91m
Enterprise Value $108.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 14.06
P/S ratio (TTM) P/S ratio 10.64
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 248.39%
Revenue (TTM) Revenue $7.70m
EBIT (operating result TTM) EBIT $-24.65m
Free Cash Flow (TTM) Free Cash Flow $-19.60m
Cash position $23.59m
EPS (TTM) EPS $-0.45
P/E forward negative
P/S forward 53.95
EV/Sales forward 71.33
Short interest 2.50%
Show more

Is Clearside Biomedical, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Clearside Biomedical, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Clearside Biomedical, Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Clearside Biomedical, Inc. forecast:

Buy
100%

Financial data from Clearside Biomedical, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
7.70 7.70
248% 248%
100%
- Direct Costs 0.17 0.17
73% 73%
2%
7.54 7.54
377% 377%
98%
- Selling and Administrative Expenses 12 12
4% 4%
150%
- Research and Development Expense 20 20
5% 5%
266%
-24 -24
18% 18%
-318%
- Depreciation and Amortization 0.17 0.17
143% 143%
2%
EBIT (Operating Income) EBIT -25 -25
18% 18%
-320%
Net Profit -32 -32
15% 15%
-414%

In millions USD.

Don't miss a Thing! We will send you all news about Clearside Biomedical, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Clearside Biomedical, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
- Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery - - Multiple Events at Asia-Pacific Vitreo-Retina Society Congress Highlighting Clearside's Pipeline Programs and Suprachoroidal Delivery Technology - - Oral Presentations Delivered on ODYSSEY Wet AMD Topline Results – ALPHARETTA, Ga., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedic...
Neutral
Seeking Alpha
13 days ago
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Victor Chong - Chief Medical Officer Charlie Deignan - CFO Conference Call Participants Annabel Samimy - Stifel Andreas Argyrides - Oppenheimer Debanjana Chatterjee - JonesTrading Operator Greetings, and welcome to the Clearside Biom...
Neutral
GlobeNewsWire
19 days ago
- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside's Suprachoroidal Space (SCS ® ) Delivery Platform - ALPHARETTA, Ga., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the b...
More Clearside Biomedical, Inc. News

Company Profile

Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Head office United States
CEO George Lasezkay
Employees 30
Founded 2011
Website www.clearsidebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today